Our Pricing

Mounjaro Lowest Price UK - From £135.00 First Order

Searching for mounjaro lowest price uk online with transparent costs and expert clinical support? Cured Pharmacy offers genuine UK-licensed Mounjaro (tirzepatide) pens from £135.00, with all prices displayed upfront before your free consultation. Our UK-registered prescribers assess your suitability in under 3 minutes, ensuring you receive safe, effective treatment at the lowest guaranteed price in the UK.

How Mounjaro Delivers Superior Weight Loss Results

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced metabolic effects that regulate appetite, slow gastric emptying, and improve insulin sensitivity.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks—significantly higher than other licensed weight loss medications [1]. The dual-receptor mechanism appears to produce greater appetite suppression and more sustained weight loss compared to GLP-1-only treatments, making Mounjaro particularly effective for patients who haven't achieved their goals with previous interventions [2].

Clinical data shows that approximately 91% of patients on the highest Mounjaro dose achieved at least 5% body weight reduction, with 57% achieving 20% or greater reduction [1]. These results represent some of the most substantial weight loss outcomes seen in obesity pharmacotherapy trials to date, though individual results vary based on adherence, lifestyle modifications, and metabolic factors.

Mounjaro Lowest Price UK: Transparent Pricing Explained

At Cured Pharmacy, Mounjaro starts from £135.00 per treatment cycle, with all costs displayed before you begin your clinical consultation. This transparent pricing model eliminates hidden fees and ensures you understand the total investment in your weight management journey from the outset. Our pricing includes the medication, clinical assessment by a UK-registered prescriber, and discreet delivery to your address.

The final cost depends on your prescribed maintenance dose, which your prescriber determines based on your individual response, tolerability, and weight loss goals. Mounjaro follows a dose-escalation schedule starting at 2.5mg weekly, gradually increasing to maintenance doses of 5mg, 10mg, or 15mg to optimise efficacy whilst minimising gastrointestinal side effects [3]. Your prescriber will review your progress at each stage and adjust accordingly.

We guarantee the lowest Mounjaro prices in the UK without compromising on clinical safety or medication authenticity. Every pen is sourced directly from licensed UK wholesalers and dispensed by our GPhC-registered pharmacy under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Unlike grey-market suppliers, we provide full traceability and regulatory compliance for every prescription.

What's Included in Your Mounjaro Price

Your Mounjaro treatment from Cured Pharmacy includes a comprehensive clinical assessment by a UK-registered prescriber who reviews your medical history, current medications, and weight management goals. The consultation takes under 3 minutes to complete online, and our clinical team typically reviews submissions within hours during working days. If approved, your prescription is sent electronically to our pharmacy for same-day dispatch in discreet, unmarked packaging with tracked delivery.

Comparing Mounjaro to Other Weight Loss Treatments

The UK weight loss medication landscape includes several MHRA-licensed options, each with distinct mechanisms, efficacy profiles, and administration schedules. Mounjaro's dual-receptor approach differentiates it from single-pathway GLP-1 treatments, whilst oral medications like orlistat work through an entirely different fat-absorption mechanism. Understanding these differences helps you and your prescriber select the most appropriate treatment for your circumstances.

Injectable GLP-1 and dual-agonist medications like Mounjaro, Wegovy, and Saxenda all work by mimicking natural hormones that regulate appetite and glucose metabolism. However, tirzepatide's dual GIP/GLP-1 action produces greater average weight loss in head-to-head trials compared to semaglutide (Wegovy's active ingredient) [4]. Both require once-weekly subcutaneous injections, whilst Saxenda requires daily administration due to its shorter-acting liraglutide formulation.

Orlistat-based treatments represent a non-systemic alternative that works in the digestive system to block approximately 30% of dietary fat absorption [5]. Whilst generally well-tolerated with fewer contraindications than injectable treatments, orlistat produces more modest weight loss—typically 5-10% body weight reduction when combined with calorie restriction. It may suit patients who prefer oral medication or have medical conditions that preclude injectable treatments.

Choosing Between Injectable and Oral Options

Your UK prescriber will assess factors including your BMI, previous weight loss attempts, medical history, and personal preferences when recommending treatment. Injectable medications typically produce greater weight loss but require comfort with self-administration and carry specific contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3]. Oral treatments may be more suitable for patients with needle phobia or those seeking a non-systemic approach, though they generally require stricter dietary fat restriction to minimise gastrointestinal side effects.

Clinical Evidence: What the Trials Show

The SURMOUNT clinical trial programme provides the most comprehensive evidence base for tirzepatide in weight management. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, randomising them to tirzepatide 5mg, 10mg, 15mg, or placebo for 72 weeks alongside lifestyle interventions [1]. The trial demonstrated dose-dependent weight loss, with the 15mg group achieving mean reductions of 22.5% compared to 2.4% in the placebo group.

Importantly, weight loss with Mounjaro occurred progressively throughout the trial period, with most participants continuing to lose weight beyond 48 weeks—suggesting the medication supports sustained metabolic changes rather than short-term appetite suppression alone [1]. Cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers also improved significantly across all tirzepatide doses, indicating broader metabolic benefits beyond weight reduction.

The SURMOUNT-2 trial specifically examined tirzepatide in patients with type 2 diabetes, demonstrating similar weight loss efficacy alongside improvements in glycaemic control [6]. This dual benefit makes Mounjaro particularly valuable for patients managing both obesity and diabetes, though prescribers must carefully monitor blood glucose levels and adjust other diabetes medications to prevent hypoglycaemia during treatment initiation.

How to Start Mounjaro Treatment at the Lowest UK Price

Beginning your Mounjaro journey at Cured Pharmacy requires completing a brief online clinical assessment that takes under 3 minutes. You'll provide information about your current weight, height, medical history, existing medications, and any previous weight loss attempts. This information allows our UK-registered prescribers to determine whether Mounjaro is clinically appropriate and safe for your individual circumstances.

If your prescriber approves Mounjaro, they'll issue an electronic prescription specifying your starting dose—typically 2.5mg weekly for the first four weeks. This gradual dose escalation minimises gastrointestinal side effects whilst your body adjusts to the medication [3]. Your prescription is sent directly to our GPhC-registered pharmacy, where we dispense genuine UK-licensed Mounjaro KwikPens and arrange discreet next-day delivery to your specified address.

You'll receive comprehensive administration instructions with your first delivery, including guidance on injection technique, site rotation, and proper pen storage. Mounjaro pens should be stored in the refrigerator at 2-8°C until first use, though they may be kept at room temperature (up to 30°C) for up to 21 days if needed [7]. Our pharmacy team remains available throughout your treatment to answer questions about administration, side effects, or prescription management.

Ongoing Support and Prescription Management

Mounjaro requires ongoing prescriber oversight to monitor your response, adjust dosing, and ensure continued safety. After your initial prescription, you'll complete follow-up assessments at regular intervals—typically every 8-12 weeks—where your prescriber reviews your weight loss progress, side effect profile, and any changes to your medical situation. These consultations ensure your treatment remains optimised and clinically appropriate as you progress toward your weight management goals.

Safety Considerations and Common Side Effects

Like all GLP-1 receptor agonists, Mounjaro commonly causes gastrointestinal side effects, particularly during dose escalation. Clinical trials reported nausea in approximately 25-33% of participants, with diarrhoea, constipation, and decreased appetite also frequently observed [1]. These effects typically diminish over time as your body adapts to the medication, and the gradual dose-escalation schedule specifically aims to minimise their severity.

More serious but rare adverse effects include pancreatitis, gallbladder disease, and acute kidney injury secondary to severe dehydration from persistent vomiting or diarrhoea [3]. Your prescriber will screen for risk factors during your initial assessment, and you should seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of dehydration whilst taking Mounjaro. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Mounjaro may interact with other medications, particularly those with narrow therapeutic windows or those affected by delayed gastric emptying. If you take oral contraceptives, your prescriber may recommend switching to non-oral contraception or using backup methods during the first four weeks of treatment and for four weeks after each dose increase [7]. Patients taking insulin or insulin secretagogues require careful dose adjustments to prevent hypoglycaemia as Mounjaro improves glycaemic control.

Who Cannot Take Mounjaro

Mounjaro is not suitable for everyone. Contraindications include pregnancy or breastfeeding, personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and previous severe hypersensitivity reactions to tirzepatide or any excipients [3]. Your UK prescriber will carefully review your medical history during consultation to ensure Mounjaro is safe and appropriate for your individual circumstances. Patients with severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease, may require alternative treatments due to Mounjaro's effects on gastric motility.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14788
4. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
6. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
7. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) injection: Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and past clinical trial outcomes do not guarantee specific results for any patient.